Acadian Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Acadian Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45K	Buy	28,129 +532	+2%	+$835	﹤0.01%	1860
2026 Q1	$38K	Sell	27,597 -1,776,520	-98%	-$2.7M	﹤0.01%	1885
2025 Q4	$3.58M	Sell	1,804,117 -49,305	-3%	-$75.8K	0.01%	737
2025 Q3	$3.01M	Buy	+1,853,422	New	+$3.62M	0.01%	781
2025 Q1	–	Sell	-56,273	Closed	-$131K	–	1603
2024 Q4	$131K	Buy	+56,273	New	+$190K	﹤0.01%	1321
2023 Q2	–	Sell	-12,192	Closed	-$22K	–	1722
2023 Q1	$22K	Sell	12,192 -9,833	-45%	-$19.2K	﹤0.01%	1641
2022 Q4	$40K	Buy	+22,025	New	+$55.7K	﹤0.01%	1609
2022 Q3	–	Sell	-34,888	Closed	-$98K	–	1668
2022 Q2	$98K	Buy	+34,888	New	+$106K	﹤0.01%	1359
2021 Q4	–	Sell	-31,289	Closed	-$204K	–	1667
2021 Q3	$204K	Buy	+31,289	New	+$198K	﹤0.01%	1288
2020 Q4	–	Sell	-2,062	Closed	-$24K	–	2195
2020 Q3	$24K	Sell	2,062 -2,233	-52%	-$32.4K	﹤0.01%	2036
2020 Q2	$69K	Buy	+4,295	New	+$47.6K	﹤0.01%	1819

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management's AUTL Position: Q2 2026 in Review

Acadian Asset Management increased its Autolus Therapeutics (AUTL) stake by 1.9% in Q2 2026, buying an estimated $835 and bringing the position to 28,129 shares worth $45K. The position accounts for ﹤0.01% of the portfolio, ranked #1860.

Acadian Asset Management first reported a position in AUTL in Q2 2020 and has held it in 11 quarters since. The position peaked at $3.58M in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

Acadian Asset Management held 28,129 shares of Autolus Therapeutics worth $45K as of Q2 2026.
Acadian Asset Management bought 532 Autolus Therapeutics shares in Q2 2026, an estimated $835.
Autolus Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1860 holding.
Acadian Asset Management first reported a position in Autolus Therapeutics in Q2 2020 and has held it in 11 quarters since.
Acadian Asset Management's Autolus Therapeutics position peaked at $3.58M in Q4 2025.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.